Published in Br J Cancer on July 03, 2006
IAPs: what's in a name? Mol Cell (2008) 3.66
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Targeting the ubiquitin system in cancer therapy. Nature (2009) 3.27
Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov (2010) 2.90
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Ther (2009) 1.25
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Biomarkers of apoptosis. Br J Cancer (2008) 1.01
Targeting cell death signaling in colorectal cancer: current strategies and future perspectives. World J Gastroenterol (2014) 0.87
Pharmacodynamic modelling of biomarker data in oncology. ISRN Pharmacol (2012) 0.85
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer (2012) 0.84
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer (2012) 0.77
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Br J Cancer (2016) 0.75
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer. Invest New Drugs (2012) 0.75
Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 9.57
Intrinsic tumour suppression. Nature (2004) 8.73
Bioanalytical method validation--a revisit with a decade of progress. Pharm Res (2000) 6.83
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem (1994) 6.32
Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer (2004) 4.73
Cell death independent of caspases: a review. Clin Cancer Res (2005) 3.85
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol (1999) 3.28
Apoptosis-targeted therapies for cancer. Cancer Cell (2003) 2.67
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology (2004) 2.41
Targeting XIAP for the treatment of malignancy. Cell Death Differ (2006) 2.04
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene (2003) 2.03
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res (2004) 2.03
Apoptosis generates stable fragments of human type I keratins. J Biol Chem (1997) 1.72
Clinical utility of cytokeratins as tumor markers. Clin Biochem (2004) 1.63
Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest (2005) 1.55
14-3-3 proteins associate with phosphorylated simple epithelial keratins during cell cycle progression and act as a solubility cofactor. J Cell Biol (1996) 1.48
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 1.47
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res (2005) 1.44
Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res (2004) 1.42
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res (2003) 1.39
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer (2005) 1.36
Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics (2000) 1.33
Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res (2001) 1.32
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis (2003) 1.30
A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J Cell Sci (1993) 1.28
Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther (2002) 1.26
Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer (2003) 1.24
Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock (2004) 1.20
Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J (1984) 1.09
Heterotypic interactions and filament assembly of type I and type II cytokeratins in vitro: viscometry and determinations of relative affinities. Eur J Cell Biol (1997) 1.09
The quest for the function of simple epithelial keratins. Bioessays (2003) 1.06
Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem (1996) 1.06
Apoptotic markers in cancer. Clin Biochem (2004) 1.05
Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol (2003) 1.00
Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640. Ann N Y Acad Sci (2005) 1.00
The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer (2001) 1.00
Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat (2005) 0.99
Cytokeratins and tissue polypeptide antigen. Int J Biol Markers (1994) 0.96
Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol (2003) 0.95
Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res (2002) 0.93
M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med (2000) 0.89
Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.86
Plakin proteins are coordinately cleaved during apoptosis but preferentially through the action of different caspases. Exp Dermatol (2004) 0.84
Therapy control in oncology by circulating nucleosomes. Ann N Y Acad Sci (2004) 0.84
Analytical validation of a real-time reverse transcription-polymerase chain reaction quantitation of different transcripts of the Wilms' tumor suppressor gene (WT1). Anal Biochem (2002) 0.83
Gene expression profile of inflammatory neutrophils: alterations in the inhibitors of apoptosis proteins during spontaneous and delayed apoptosis. Shock (2004) 0.82
A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol (2004) 0.81
Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis. Leukemia (2002) 0.80
Biomarker boom slowed by validation concerns. J Natl Cancer Inst (2004) 0.79
Type I keratin 16 forms relatively unstable tetrameric assembly subunits with various type II keratin partners: biochemical basis and functional implications. Biol Bull (1998) 0.78
A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Scand J Clin Lab Invest (1995) 0.78
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J (1993) 3.75
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol (1999) 3.18
IgA subclasses in various secretions and in serum. Immunology (1982) 2.43
Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem (2009) 2.09
Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J Clin Invest (1983) 1.86
Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J Clin Invest (1982) 1.84
'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods (2009) 1.81
Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci (1996) 1.80
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst (2000) 1.77
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Nature and origin of the proteins of bile. I. A comparative analysis of serum and bile proteins in man. Eur J Clin Invest (1974) 1.59
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res (1993) 1.59
Identification of a minimal hydrophobic domain in the herpes simplex virus type 1 scaffolding protein which is required for interaction with the major capsid protein. J Virol (1996) 1.56
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer (2009) 1.50
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Apoptosis and cancer chemotherapy. Trends Cell Biol (2001) 1.48
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer (2004) 1.45
Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest (1984) 1.44
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Transport of animals. Vet Rec (1995) 1.39
Origin and nature of the proteins of bile. II. A comparative analysis of serum, hepatic lymph and bile proteins in the dog. Eur J Clin Invest (1974) 1.38
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer (2005) 1.36
Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci (1990) 1.34
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol (2001) 1.32
Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol (2008) 1.32
Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J (2001) 1.32
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death. Cell Death Differ (2003) 1.27
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene (2008) 1.26
Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med (1997) 1.24
Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol (1999) 1.24
Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. Oncogene (2001) 1.23
Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer (2013) 1.21
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci (1996) 1.20
Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res (1993) 1.20
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol (2007) 1.19
DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev (2004) 1.19
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer (2006) 1.18
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene (2009) 1.17
Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol (1998) 1.17
Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Am J Physiol (1996) 1.15
Bid, a widely expressed proapoptotic protein of the Bcl-2 family, displays lipid transfer activity. Mol Cell Biol (2001) 1.13
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer (2012) 1.11
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3. J Virol (2000) 1.10
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer (2010) 1.08
Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed (2002) 1.07
Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology (1991) 1.07
Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol (1997) 1.07
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer (2000) 1.07
The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta (1997) 1.05
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05
Age and ceftriaxone kinetics. Clin Pharmacol Ther (1984) 1.04
Dynamic CT in pancreatic lymphoma. J Comput Assist Tomogr (1993) 1.04
VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer (1995) 1.04
Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol (1996) 1.03
Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases. Dig Dis Sci (1982) 1.02
The liver in the IgA secretory immune system. Dogs, but not rats and rabbits, are suitable models for human studies. Hepatology (1983) 1.01
Biomarkers of apoptosis. Br J Cancer (2008) 1.01
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer (2011) 1.00
Jejunal immunoglobulin and antigliadin antibody secretion in adult coeliac disease. Gut (1990) 1.00
Virus-specific interaction between the human cytomegalovirus major capsid protein and the C terminus of the assembly protein precursor. J Virol (1996) 1.00
Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother (1994) 1.00
IAPs as a target for anticancer therapy. Curr Cancer Drug Targets (2007) 0.98
Controlled trial of cimetidine in reflux esophagitis. Dig Dis Sci (1980) 0.97
Circulating immune complexes and disease activity in Crohn's disease. Gut (1978) 0.97
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res (1993) 0.97
Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2. Biochemistry (1997) 0.96
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer (2009) 0.95
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark (2009) 0.95
A randomized double-blind crossover study of indoor air filtration and acute changes in cardiorespiratory health in a First Nations community. Indoor Air (2013) 0.95
Regional nerve block allows for optimization of planning in the creation of arteriovenous access for hemodialysis by improving superficial venous dilatation. Ann Vasc Surg (2007) 0.94
Studies of the proteins of secretions from two villous tumours of the rectum. Gastroenterologia (1966) 0.94
The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion. J Neuroimmunol (1997) 0.94
Intestinal development in the suckling rat: effect of insulin on the maturation of villus and crypt cell functions. Eur J Clin Invest (1988) 0.93
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. J Immunol Methods (2010) 0.93
Evaluation of glutathione-sensitive fluorescent dyes in cortical culture. Glia (2000) 0.93
A longitudinal investigation of psychological morbidity in patients with ovarian cancer. Br J Cancer (2008) 0.93
Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. Cell Death Differ (2013) 0.93
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer (2009) 0.93
Quantitative multiplexed quantum dot immunohistochemistry. Biochem Biophys Res Commun (2008) 0.92